Sliwa Marcin, Markovic Darko, Gabrusiewicz Konrad, Synowitz Michael, Glass Rainer, Zawadzka Malgorzata, Wesolowska Aleksandra, Kettenmann Helmut, Kaminska Bozena
Laboratory of Transcription Regulation, Department of Cell Biology, Nencki Institute of Experimental Biology, Warsaw, Poland.
Brain. 2007 Feb;130(Pt 2):476-89. doi: 10.1093/brain/awl263. Epub 2006 Nov 14.
The invasion of tumour cells into brain tissue is a pathologic hallmark of WHO grades II-IV gliomas and contributes significantly to the failure of current therapeutic treatments. Activated microglial cells are abundant in brain tumours and may support tumour invasiveness. We have previously demonstrated that cyclosporin A (CsA) can affect growth of glioma cells in vitro by inhibiting signalling pathways, which are essential for tumour proliferation and invasiveness. In this work, we demonstrate that migration of EGFP-transfected glioblastoma cells in organotypic brain slices was significantly inhibited by treatment with CsA. On average 77% of untreated cells migrated beyond 500 mum, while only 28-33% cells migrated as far in the brain slices treated with CsA (P < 0.001). This inhibitory effect on glioblastoma invasion was lost when glioblastoma cells were injected into microglia-depleted brain slices. Moreover, CsA significantly inhibits intracranial glioma growth in vivo. We demonstrate that microglia-derived factors increase glioma invasiveness in Matrigel assay in vitro and this is associated with activation of the PI-3K/Akt signalling pathway. The invasion promoting effect of microglia is abolished in the presence of CsA. Furthermore, glioma-derived soluble factors induce morphological transformation of microglia and activate MAPK signalling, although production of pro-inflammatory factors was not observed. Our findings that CsA interferes at clinically relevant concentrations with the tumour-promoting role of microglia and impairs invasive growth of glioma cells in vivo may provide a novel therapeutic strategy against gliomas.
肿瘤细胞侵入脑组织是世界卫生组织II-IV级胶质瘤的病理标志,也是导致当前治疗失败的重要原因。活化的小胶质细胞在脑肿瘤中大量存在,可能支持肿瘤的侵袭性。我们之前已经证明,环孢素A(CsA)可以通过抑制对肿瘤增殖和侵袭至关重要的信号通路来影响胶质瘤细胞的体外生长。在这项研究中,我们证明用CsA处理可显著抑制转染EGFP的胶质母细胞瘤细胞在器官型脑片中的迁移。未经处理的细胞平均有77%迁移超过500μm,而在用CsA处理的脑片中,只有28%-33%的细胞能迁移到同样的距离(P<0.001)。当将胶质母细胞瘤细胞注射到小胶质细胞缺失的脑片中时,这种对胶质母细胞瘤侵袭的抑制作用消失。此外,CsA在体内可显著抑制颅内胶质瘤的生长。我们证明小胶质细胞衍生因子在体外基质胶实验中可增加胶质瘤的侵袭性,这与PI-3K/Akt信号通路的激活有关。在CsA存在的情况下,小胶质细胞的侵袭促进作用被消除。此外,胶质瘤衍生的可溶性因子可诱导小胶质细胞形态转化并激活MAPK信号通路,尽管未观察到促炎因子的产生。我们的研究结果表明,CsA在临床相关浓度下可干扰小胶质细胞的促肿瘤作用并损害胶质瘤细胞在体内的侵袭性生长,这可能为胶质瘤提供一种新的治疗策略。